Long‐term effect of human mini‐dystrophin in transgenic mdx mice improves muscle physiological function

Duchenne muscular dystrophy (DMD) is a lethal genetic muscle disorder caused by recessive mutations in dystrophin gene, affecting 1/3000 males. Gene therapy has been proven to ameliorate dystrophic pathology. To investigate therapeutic benefits from long‐term effect of human mini‐dystrophin and functional outcomes, transgenic mdx mice (Tg‐ mdx ) containing a single copy of human mini‐ dystrophin (∆hDys3849) gene, five rods (Rods1‐2, Rods22‐24), and two hinges (H1 and H4) driven by a truncated creatine‐kinase promoter (dMCK) in a recombinant adeno‐associated viral vector (rAAV) backbone, were generated and used to determine gene expression and improvement of muscle function. Human mini‐ dystrophin gene expression was found in a majority of the skeletal muscles, but no expression in cardiac muscle. Dystrophin‐associated glycoproteins (DAGs) such as sarcoglycans and nNOS were restored at the sarcolemma and coincided with human mini‐ dystrophin gene expression at the ages of 6, 10, and 20 months; Morphology of dystrophic muscle expressing the human mini‐ dystrophin gene was improved and central nuclei were reduced. Myofiber membrane integrity was improved by Evans blue dye test. Improvement in treadmill running and grip force was observed in transgenic mice at 6 months. Tetanic force and specific force of tibialis anterior (TA) muscle were significantly increased at the ages of 6, 10, and 20 months. Pseudohypertrophy was not found in TA muscle at 10 and 20 months when compared with wild‐type C57 (WT) group. This study demonstrated that the long‐term effects of human mini‐dystrophin effectively ameliorated pathology and improved the functions of the dystrophic muscles in the transgenic DMD mouse model.